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Age-related macular degeneration (AMD) is a major cause of blindness, but presents differently in Europeans and
Asians. Here, we perform a genome-wide and exome-wide association study on 2,119 patients with exudative AMD
and 5,691 controls, with independent replication in 4,226 patients and 10,289 controls, all of East Asian descent, as
part of The Genetics of AMD in Asians (GAMA) Consortium. We ﬁnd a strong association between CETPAsp442Gly
(rs2303790), an East Asian-speciﬁc mutation, and increased risk of AMD (odds ratio (OR)¼ 1.70, P¼ 5.60 10 22).
The AMD risk allele (442Gly), known to protect from coronary heart disease, increases HDL cholesterol levels by
0.17mmol l 1 (P¼ 5.82 10 21) in East Asians (n¼ 7,102). We also identify three novel AMD loci: C6orf223
Ala231Ala (OR¼0.78, P¼ 6.19 10 18), SLC44A4 Asp47Val (OR¼ 1.27, P¼ 1.08 10 11) and FGD6 Gln257Arg
(OR¼0.87, P¼ 2.85 108). Our ﬁndings suggest that some of the genetic loci conferring AMD susceptibility in
East Asians are shared with Europeans, yet AMD in East Asians may also have a distinct genetic signature.
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A
ge-related macular degeneration (AMD) is a progressive,
blinding disease affecting millions of elderly individuals
worldwide1,2. Several genome-wide association studies
(GWAS) have identiﬁed common variants associated with AMD
in European-ancestry populations3–6, and recently, rare genetic
variation at CFH, CFI, C3 and C9 were also shown to strongly
associate with AMD in Europeans7–10. However, there are few
such studies in Asians11. Importantly, Asians appear to have a
distinct clinical presentation of the disease (for example, absence
of drusen and minimal ﬁbrous scarring in polypoidal choroidal
vasculopathy, a variant of AMD accounting for 20–55% of Asian
patients with exudative AMD) and different responses to
treatment (for example, poorer response to inhibitors of
vascular endothelial growth factor (VEGF) compared with
patients of European ancestry)12,13. It remains unclear whether
there are differences in underlying genetic characteristics of AMD
between patients of Asian versus European ancestry.
Concurrently, previous GWAS studies provide limited cover-
age of low-frequency coding variants, which may result in the loss
of function and are often ethnic-speciﬁc. There is thus interest in
genetic studies of AMD and other diseases beyond standard-
content GWAS to discover potentially causative coding variants
in different ethnic groups.
To address these questions, the Genetics of AMD in Asians
Consortium perform a genome-wide (GWAS) and exome-wide
association study (EWAS) of advanced AMD solely on the
exudative (neovascular) disease subtype in East Asians. Com-
pared with standard-content GWAS arrays, the exome array has
signiﬁcantly increased marker density across the coding human
exome, thus increasing power to detect disease associations
located within the coding frame. EWAS of AMD have not been
previously conducted in either Europeans or Asians. In this
paper, we present data from eight independent AMD case–
control collections enrolled across multiple sites in East Asia,
totalling 6,345 exudative AMD cases and 15,980 controls. This is
the largest sample, to our knowledge, of East Asians ever
assembled for genetic studies of AMD.
Results
Association with previously identiﬁed AMD variants. After
genotype imputation, synchronization and stringent quality ﬁlters
were performed, a total of 4,471,719 SNPs were assessed for the
GWAS and 120,027 autosomal coding-frame SNPs for EWAS
from 2,119 AMD cases and 5,691 controls (Table 1). Overall
genomic inﬂation was very low (lgc¼ 1.031; Supplementary
Fig. 1), suggesting minimal confounding of the disease association
analysis by population stratiﬁcation or other systematic study
design biases. Data from the discovery stage analysis conﬁrmed
previously identiﬁed AMD variants in ARMS2-HTRA1
rs10490924 (P¼ 1.20 10 103), CFH rs10737680 (P¼ 7.54
10 38), CETP rs3764261 (P¼ 1.66 10 12), ADAMTS9
rs6795735 (P¼ 1.13 10 5), C2-CFB rs429608 (P¼ 1.06
10 4), as well as CFI rs4698775 (P¼ 7.5 10 4; Supplementary
Table 1 and Supplementary Fig. 2). Our data also showed
nominal evidence of replication in the same direction as the
initial study for a further three previously reported variants
(TGFBR1 rs334353, APOE rs4420638, and VEGFA rs943080;
Po0.05 for each). The remaining 8 out of 17 previously described
SNPs that were non-monomorphic in our East Asian
collections did not show evidence of replication in our study
(Supplementary Table 1). A recently described rare, functional
and highly penetrant genetic mutation within CFI (G119R,
rs141853578) shown to confer markedly elevated risk of AMD in
Europeans14 was observed to be non-polymorphic in our East
Asian samples (Supplementary Table 1). Similarly, recently
described rare mutations in C3 (K155Q, rs147859257) and C9
(P167S, rs34882957) were also shown to be non-polymorphic in
our East Asian samples (Supplementary Table 1).
Discovery of new SNP variants associated with AMD. Apart
from verifying previous observations, our discovery analysis also
revealed genome-wide signiﬁcant association at C6orf223
(rs2295334 encoding for A231A, P¼ 1.41 10 8; Table 2,
Supplementary Table 2 and Supplementary Fig. 2), a novel SNP
marker not previously reported to associate with AMD risk. We
observed a further 21 independent SNPs from distinct loci not
previously implicated with susceptibility to AMD showing
evidence of association surpassing Po1 10 4. We then
brought forward all the 22 markers (Table 2) for replication
genotyping in independent sample collections comprising 4,226
exudative AMD cases and 10,289 controls (Table 1). Replication
evidence was compelling for CETP rs2303790 (encoding D442G;
odds ratio (OR)¼ 1.73, P¼ 2.95 10 16), as well as for C6orf223
rs2295334 (A231A; OR¼ 0.80, P¼ 5.25 10 11), SLC44A4
rs12661281 (D47V; OR¼ 1.22, P¼ 5.13 10 6) and FGD6
rs10507047 (Q257R; OR¼ 0.88, P¼ 7.69 10 5), leading to
genome-wide signiﬁcant ﬁndings in the meta-analysis of all 6,345
Table 1 | Baseline characteristics of exudative age-related macular degeneration cases and controls in the discovery and
replication sample collections.
Sample collection Ethnicity No. of cases* No. of controls* AMD phenotyping Genotyping platform
Discovery
Singapore Chinese 631 1,967 Dilated fundoscopy, FA, ICG & OCT Illumina OmniExpress, 610K & Exome Chips
Hong Kong Chinese 507 2,967 Dilated fundoscopy, FA & ICG Illumina OmniExpress & Exome Chips
Japan Japanese 981 757 Dilated fundoscopy, FA, ICG & OCT Illumina OmniExpress & Exome Chips
Subtotal 2,119 5,691
Replication
Korea Korean 757 1,829 Dilated fundoscopy, FA, ICG & OCT Sequenom MassArray & Taqman
Japan Japanese 1,213 4,035 Dilated fundoscopy, FA, ICG & OCT Sequenom MassArray & Taqman
Guangdong, China Chinese 398 2,478 Dilated fundoscopy, FA & ICG Sequenom MassArray & Taqman
Sichuan, China Chinese 1,055 1,089 Dilated fundoscopy, FA & ICG SNAPSHOT
Beijing, China Chinese 803 858 Dilated fundoscopy, FA, ICG & OCT Sequenom MassArray & Taqman
Subtotal 4,226 10,289
All samples 6,345 15,980
AMD, age-related macular degeneration; FA, ﬂuorescein angiography; ICG, indocyanine green angiography; OCT, optical coherence tomography.
*No. of samples reﬂect those passing quality checks.
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AMD cases and 15,980 controls (Po5.0 10 8 for each of the
four loci; Table 2 and Supplementary Table 2). Genotyping
clusters were directly visualized for the top SNPs and conﬁrmed
to be of good quality (Supplementary Fig. 3).
Of note, we did not observe any substantial difference in the
association signals of the most signiﬁcant SNPs in the subgroup
analysis of our AMD cases by typical neovascular AMD (n¼ 1,083
cases) and polypoidal choroidal vasculopathy (n¼ 1,015 cases;
Supplementary Table 3). The effect size for each of the top SNPs
was similar between the two AMD subgroups.
Conditional analysis. The presence of the mutant CETP 442G
(rs2303790) allele is seen only in East Asians (for example, Chinese,
Japanese and Koreans; minor allele frequency (MAF)o5% in our
controls) and not in South Asians, Europeans or Africans. This
mutation is independent from all previously described common,
non-coding polymorphisms near the CETP locus (r2o0.1;
Supplementary Fig. 4). Regional association analysis conditioning
on other known common AMD variants in CETP conﬁrmed the
independence of D442G from other nearby common variants
(Supplementary Tables 4 and 5). We also genotyped and assessed
multiple, rare, protein-changing mutations at CETP, including
Y74Stop, G331S, N358S and A390P (Fig. 1). None of them
showed association with AMD (Table 3). Mutational load and
haplotypic analysis considering all amino-acid changes within
CETP conﬁrmed that the D442G mutation drove all signals of
association between CETP and AMD (Table 4).
C6orf223 is located B220,000 base pairs downstream of
VEGFA and B150,000 base pairs from rs943080, a marker
previously shown to strongly associate with AMD in
Europeans5,6. In this study of AMD in East Asians, the
evidence of association for VEGFA rs943080 was only
nominally signiﬁcant (P¼ 0.041 in the discovery stage;
Supplementary Table 1). Linkage disequilibrium analysis
revealed no correlation between C6orf223 rs2295334 and
VEGFA rs943080 (r2¼ 0.0), with both markers separated by
signiﬁcant recombination events (Fig. 2a). Logistic regression
adjusting for the allele dosage at VEGFA rs943080 did not reveal
any attenuation of the association signal for C6orf223 rs2295334
(P¼ 1.66 10 8; Supplementary Table 6). Regional association
Table 2 | Summary of results of the genome-wide and exome-wide association study on exudative age-related macular
degeneration.
SNP Chr Position Nearest gene Minor allele Discovery (2,119/
5,691)*
Replication (4,226/
10,289)*
Combined (6,345/
15,980)*
OR Pdiscovery OR Preplication OR Pcombined
Loci reaching Pdiscoveryo1 104 and Pcombinedo5 10 8
rs2303790 16 57,017,292 CETP G 1.69 3.36 10 7 1.73 2.95 10 16 1.70 5.60 10 22w
rs2295334 6 43,970,827 C6orf223 A 0.75 1.41 10 8 0.80 5.25 10 11 0.78 6.19 10 18z
rs12661281 6 31,842,598 SLC44A4 T 1.38 1.23 10 7 1.22 5.13 106 1.27 1.08 10 11y
rs10507047 12 95,604,290 FGD6 G 0.83 4.75 10 5 0.88 7.69 10 5 0.87 2.85 10 8w
Loci reaching Pdiscoveryo1 104 but PcombinedZ5 10 8
rs62191056 2 227,779,676 RHBDD1 A 1.33 2.27 10 5 1.14 0.046 1.23 1.10 10 5
rs7274811 20 32,333,181 ZNF341 T 0.83 5.72 10 5 0.92 0.011 0.89 1.26 10 5
rs3894326 19 5,843,784 FUT3 T 0.75 6.22 106 0.91 0.27 0.81 1.85 10 5
rs117581914 19 9,236,724 OR7G3 G 2.02 3.27 10 5 1.36 0.19 1.78 3.05 10 5
rs2287921 19 49,228,272 RASIP1 C 1.74 7.70 10 6 1.20 0.13 1.43 3.56 10 5
rs17143419 7 70,829,578 WBSCR17 T 1.49 2.28 10 5 1.12 0.34 1.34 8.66 10 5
rs4280803 4 57,760,424 REST|| T 0.79 4.87 10 5 0.65 0.76 0.79 4.68 10 5
rs202018816 19 10,445,066 ICAM3 A 5.13 1.39 10 5 1.42 0.28 2.47 2.46 104
rs7165901 15 102,021,219 PCSK6 C 0.80 1.46 10 5 0.96 0.44 0.88 3.21 104
rs1891359 10 127,495,153 UROS G 1.77 5.42 10 5 0.95 0.74 1.36 0.0044
rs215736 7 32,443,119 PDE1C-LSM5|| T 3.28 3.82 10 5 0.71 0.38 1.93 0.0049
rs2221338 2 68,224,745 C1D|| A 1.22 2.60 10 5 1.02 0.65 1.13 5.83 104
rs1538240 13 101,968,310 NALCN T 1.24 2.92 10 5 1.03 0.59 1.14 6.54 104
rs7560053 2 228,220,769 MFF T 0.83 7.00 10 5 0.98 0.76 0.90 0.0023
rs73509026 19 12,059,467 ZNF700 G 1.65 1.25 10 5 0.85 0.34 1.32 0.0039
rs1241050 4 141,410,099 LOC152586 T 0.72 3.35 10 5 1.02 0.79 0.86 0.0068
rs7612209 3 177,596,989 AK056252 A 1.21 6.45 10 5 0.93 0.11 1.06 0.087
Summary of SNPs that exceeded the threshold of Po1 104 on the basis of score-based tests using logistic regression in the discovery stage and were brought forward to the replication stage. In the
combined meta-analysis of the discovery and replication samples, four new variants (the ﬁrst four SNPs in the table) reached the threshold of genome-wide signiﬁcance (Po5 108). All of the four
new variants are coding variants (CETP rs2303790 encoding D442G; C6orf223 rs2295334 encoding A231A; SLC44A4 rs12661281 encoding D47V; and FGD6 rs10507047 encoding Q257R). Physical
positions and nearest genes are based on NCBI build 37 of the human genome.
SNP, single-nucleotide polymorphism; Chr, chromosome; OR, odds ratio for per copy of the minor allele.
*Number in parentheses presents the no. of cases and no. of controls, respectively.
wHeterogeneity I2¼0% for CETP rs2303790 and FGD6 rs10507047.
zHeterogeneity I2¼41.5%, random-effects P in the combined analysis¼ 1.61 10 13.
yHeterogeneity I2¼ 23.1%, random-effects P in the combined analysis¼ 6.91 109.
||These index SNPs are located in intergenic regions. Other index SNPs are located within the genes.
Y74*
rs201790757
G331S
rs5881
N358S
rs19018756
A390P
rs5880
D442G
rs2303790
3′5′
Figure 1 | Genomic organization of the CETP gene. The position of ﬁve
rare (minor allele frequency o0.05) amino-acid changes observed in the
discovery samples are shown as indicated by the arrows. Horizontal bars
represent the position of exons in the CETP gene.
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analysis including all markers from the genome and exome array
data conditioning on C6orf223 rs2295334 also did not reveal any
secondary signal of association within its 1Mb ﬂanking region
(Supplementary Table 7), thus pointing to C6orf223 rs2295334 as
a novel and uncharacterized genetic risk factor for exudative
AMD in East Asians.
SLC44A4 is located B116,000 base pairs away from a
previously reported AMD locus, C2-CFB (rs429608)6.
Nevertheless, SLC44A4 rs12661281 has no correlation with C2-
CFB rs429608 (r2¼ 0.01) and showed the strongest evidence of
association with AMD within the genomic region (Fig. 2b),
suggesting it to be also a new and uncharacterized risk factor for
AMD. Logistic regression analysis adjusting for allele dosage at
C2-CFB rs429608 did not result in any signiﬁcant change in
magnitude of the association either at SLC44A4 rs12661281,
testifying to their mutual independence (ORunconditioned¼ 1.38,
Punconditioned¼ 1.10 10 7; ORconditioned for rs429608¼ 1.35,
Pconditioned for rs429608¼ 1.49 10 6; Supplementary Table 8).
Gene-based tests on mutational load. We next proceeded to
conduct gene-based tests on mutational load to further investigate
the role of low-frequency variants in exudative AMD for all the
patient collections in the discovery stage. Gene-based tests are an
alternative to single-marker tests for association, which are often
underpowered to detect association with rare variants. We per-
formed our tests as previously described15. To more directly
address the impact of low-frequency, non-synonymous genetic
variants, we considered only 109,296 such variants with MAF
o5%. As a result, we were able to assess a total of 10,736 genes
having at least two such variants using the sequence kernel
association optimal (SKAT-O) test16. We did not detect signiﬁcant
evidence of association (Po5 10 8) between mutational load
and AMD at any of the 10,736 genes tested, which are consistent
across all three discovery sample collections. Nonetheless, while
looking up on previously reported 22 genes within 17 distinct loci
(Supplementary Table 1) associated with AMD in European
populations, we note nominal evidence of association between
genetic load at CETP (Punconditioned¼ 5.38 10 6), whereby the
association was almost entirely driven by D442G (Pconditioned for
D442G¼ 0.96; Table 4) as well as C2 and AMD (P¼ 1.83 10 6,
Supplementary Table 9). All the observations exceeding
Po1 10 4 for gene-based tests on mutational load
summarized across the three discovery collections are appended
as Supplementary Table 9.
CETP 442G, HDL and coronary heart disease. The mutant
CETP 442G allele was shown to result in an abnormally func-
tioning CETP protein17. As CETP is a critical component of the
pathways that regulate high-density lipoprotein cholesterol
(HDL-c)18, we assessed this mutation for associations with
serum HDL-c levels using linear regression, with adjustment for
age, gender and body mass index, in three population-based
cohorts of Singaporean Chinese19–21 and Japanese22 (n¼ 7,102,
see details on the study cohorts in Supplementary Methods)
where GWAS data were available. We noted a strong association
between 442G allele and increased HDL-c levels
(b¼ 0.174mmol l 1 per copy of 442G allele; reﬂecting an
B10% shift within the normal HDL range, P¼ 5.82 10 21;
Table 5). This effect size is at least twice that observed for other
CETP variants reported in European populations (Supplementary
Table 10)23,24.
Due to its strong effect on serum HDL-c, we assessed whether
the mutant CETP 442G allele conferred any effect on individual
susceptibility to coronary heart disease (CHD) in East Asians.
Using 683 CHD cases and 1,281 controls from the Singapore
Chinese Health Study (Supplementary Methods)25, we noted
some degree of enrichment of the HDL-increasing, mutant 442G
allele in the controls (2.89%) compared with the cases (2.42%,
Table 3 | Single variant analysis (score-based tests using logistic regression) of the ﬁve observed CETP rare variants with
exudative age-related macular degeneration in the discovery stage.
Sample collections SNP Amino-acid change A1 A2 Genotype* MAF OR P value
Cases Controls Cases Controls
Hong Kong rs201790757 Y74* C A 0/0/507 0/3/2,962 0 0.0005 N/A 1
Hong Kong rs5881 G331S A G 0/5/502 12/1/52 0.0049 0.0024 1.94 0.18
Japan rs5881 G331S A G 0/3/970 0/4/759 0.0015 0.0026 0.59 0.49
Singapore rs5881 G331S A G 0/5/635 0/21/1,935 0.0039 0.0054 0.73 0.52
Hong Kong rs190187567 N358S G A 0/0/507 0/1/2,964 0 0.0002 N/A 1
Japan rs190187567 N358S G A 0/1/972 0/0/763 0.0005 0 N/A 1
Hong Kong rs5880 A390P C G 0/5/502 0/36/2,926 0.0049 0.0061 0.81 0.66
Singapore rs5880 A390P C G 0/13/627 0/28/1,925 0.0102 0.0072 1.43 0.30
Hong Kong rs2303790 D442G G A 4/45/458 2/172/2,791 0.0523 0.0297 1.80 2.8 104
Japan rs2303790 D442G G A 4/84/885 0/41/722 0.0473 0.0269 1.79 0.0025
Singapore rs2303790 D442G G A 1/44/595 0/98/1,858 0.0359 0.0251 1.48 0.034
SNP, single-nucleotide polymorphism; A1, minor allele; A2, major allele; MAF, minor allele frequency; OR, odds ratio for per copy of the minor allele.
*Data are number of genotypes A1A1/A1A2/A2A2.
Table 4 | Results of association of the ﬁve observed CETP rare variants with exudative age-related macular degeneration using
gene-based tests in 2,119 cases and 5,691 controls in the discovery stage.
Gene No. of variants Variants (minor allele counts) Unconditional
analysis*
Conditional
analysis*
CETP 5 Tyr74*(3), Gly331Ser (56), Asn358Ser (2), Ala390Pro (81), Asp442Gly
(536)
P¼ 5.38 10 6 P¼0.96
*Gene-based tests on mutational load (additive allele based using Burden tests) at CETP, unconditioned and conditioned for CETP Asp442Gly.
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Figure 2 | Regional association plots at the three risk loci for exudative age-related macular degeneration. (a) The C6orf223 locus (rs2295334): VEGFA
rs943080, which is located in the intergenic, non-coding region, was very strongly associated with AMD in Europeans, but this study of exudative AMD in
East Asians could not reveal signiﬁcant association with it (P¼0.041 by score-based tests using logistic regression in 2,119 cases and 5,691 controls). The
two markers are independent from each other (r2¼0.0), as well as separated by strong recombination events in Asians. (b) The SLC44A4 locus
(rs12661281): C2-CFB rs429608 was very strongly associated with AMD in Europeans, but revealed modest evidence of association in our discovery stage
(P¼ 1.06 104). The two markers are independent from one another (r2¼0.01). (c) The FGD6 locus (rs10507047).
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OR¼ 0.83), although this did not reach statistical signiﬁcance
(P¼ 0.39). However, our observations were consistent with a
recent study from Japan which analysed CETP D442G in 4,399
CHD cases and 7,672 controls whereby enrichment of the 442G
allele were also found in the controls (3.4%) compared with the
CHD cases (2.8%; OR¼ 0.83, P¼ 0.02)26. We thus performed a
meta-analysis of our study and the Japanese study, resulting in a
consistent protective effect of this mutation with CHD
(OR¼ 0.83, P¼ 0.011, I2¼ 0.0%; Supplementary Fig. 5).
Discussion
Our studies of exudative AMD in East Asians identiﬁed three
novel loci (C6orf233, SLC44A4 and FGD6), two of which
(SLC44A4 and FGD6) harbour coding, non-synonymous variants.
These have not been identiﬁed in large samples of AMD patients
of European descent6, thus validating the role of searching for
coding variations in diverse ethnic groups to better understand
mechanistic basis of complex diseases such as AMD.
Our most interesting ﬁndings were the identiﬁcation of an
uncommon East Asian-speciﬁc mutation at CETP (D442G)
associated with exudative AMD. The association is the strongest
(per-allele OR¼ 1.70) observed outside of the classical CFH and
ARMS2-HTRA1 loci in East Asians. A common variant
(rs3764261) mapping to the intergenic region between HERPUD1
and CETP was previously linked to AMD in Europeans, yet its
effect size was modest (OR¼ 1.15)5 and independent from the
D442G association. The mutant 442G allele is known to impair
CETP function with reduction in plasma CETP mass and
activity17,27, and is associated with elevated HDL-c in Japanese
families17,27. This allele is absent in European populations28 and
appears to be present only in East Asians, rendering it
independent from all other previously described common, non-
coding CETP polymorphisms. We showed that each copy of the
dysfunctional 442G allele confers, on average, a rise in HDL-c
levels of 0.174mmol l 1 and conﬁrmed ﬁndings from the earlier
Japanese studies. Given the mean serum HDL-c concentration
is 1.3mmol l 1, this is a mutation of considerable effect size
even from a population-based perspective. Notably, no other
amino-acid substitutions within CETP detected by our GWAS
and EWAS showed any evidence of association with AMD (Fig. 1
and Table 3), suggesting that the D442G mutation is a possible
causative mutation of AMD in East Asians in the CETP locus. We
are not surprised that CETP D442G did not show a clearly
signiﬁcant protective effect against CHD as increasing lines of
evidence more directly implicate LDL as the driving force for
CHD susceptibility29,30.
C6orf223 is a newly mapped gene with yet unknown functional
role. Its A231A synonymous coding change is ﬁvefold rarer in
Europeans (MAF¼ 0.03) as compared with Asians (MAF40.15,
Supplementary Table 2). It is thus unsurprising that the European
GWAS efforts have yet to detect this locus. VEGFA rs943080, a
marker strongly associated with AMD in European-ancestry
populations5, is in the vicinity of C6orf223, but its association
with AMD is much weaker in this study of East
Asians (Supplementary Tables 1 and 6), possibly reﬂecting the
differences in therapeutic response to anti-VEGF treatment
between Asians and Europeans13,31.
The D47V mutation within SLC44A4 is not included in most of
the routinely used genotyping arrays, but is now included as part
of the exome array used in this study. The genomic region around
the SLC44A4 locus is more complex, being located within the
broad MHC region on Chromosome 6 between HLA class I and
class II genes. As this region is very polymorphic, and allele
frequency differences between cases and controls could be
confounded by even minor population stratiﬁcation, we thus
reassessed the associations with AMD by adjusting for the ﬁrst
10 principal components (PCs) of genetic ancestry. We did not
observe any change in the association signals observed from our
standard analysis, which adjusted for the ﬁrst ﬁve PCs (analysis
adjusting for the top 10 PCs; OR¼ 1.39, P¼ 2.33 10 7 in the
discovery phase), consistent with previous observations in Asian
studies with well-replicated associations within the MHC
region32,33. SLC44A4 encodes for choline transporter protein-4,
involved in sodium-dependent choline uptake by cholinergic
neurons34. Defects in SLC44A4 have been linked to sialidosis,
which presents with a spectrum of symptoms including eye
abnormalities35.
Prior studies on the basis of European patient collections have
identiﬁed a total of four distinct AMD-associated loci on
Chromosome 6 alone6. In this light, the burden of proof for the
positive identiﬁcation of C6orf223 and SLC44A4 (both are also
Table 5 | Association of serum HDL cholesterol level and CETP D442G in East Asian population-based cohorts.
Cohort No. of
samples
D442G
genotype
Serum HDL cholesterol mean (s.d.),
mmol l 1
Association of HDL with D442G
Effect
allele
Effect allele
frequency
Effect,*
mmol l 1
s.e.m. P value
SCES 1,922 Gly/Gly 1.46w 442Gly 0.02 0.17 0.04 1.46 10 6
Asp/Gly 1.49 (0.010)
Asp/Asp 1.32 (0.009)
SP2-set1z 1,044 Gly/Gly —w 442Gly 0.03 0.17 0.04 5.38 10 5
Asp/Gly 1.70 (0.014)
Asp/Asp 1.52 (0.011)
SP2-set2y 888 Gly/Gly —w 442Gly 0.03 0.17 0.05 3.46 104
Asp/Gly 1.59 (0.012)
Asp/Asp 1.43 (0.012)
Nagahama 3,248 Gly/Gly 2.32 (0.344) 442Gly 0.04 0.18 0.03 1.85 109
Asp/Gly 1.83 (0.030)
Asp/Asp 1.66 (0.008)
Meta-
analysis
7,102 442Gly 0.03 0.174 0.018 5.82 10 21
SCES, Singapore Chinese Eye Study; SP2, Singapore Prospective Study Program; Nagahama, Nagahama Prospective Genome Cohort for the Comprehensive Human Bioscience.
*Effect per copy of the 442Gly allele on serum HDL-c in mmol l 1.
wOnly one individual in SCES was homozygous (Gly/Gly) for the CETP 442G mutant allele. No Gly/Gly homozygotes were observed in both SP2 collections.
zGenotyped on Illumina 610K chip.
yGenotyped on Illumina 1M chip.
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located on Chromosome 6) is higher than usual due to the need
for appropriate considerations of previously reported variants on
the same chromosome. It is reassuring to note that both C6orf223
and SLC44A1 showed the strongest two signals of association
with AMD outside of CFH, ARMS2-HTRA1 and CETP. Our
exhaustive analyses using logistic regression adjusting for allele
dosages at previously described SNP markers suggest that both
C6orf223 and SLC44A1 are unrelated to those previously
reported, and thus they likely represent Asian-speciﬁc genetic
associations for AMD.
Neither FGD6 nor the genes within its vicinity (Fig. 2c) have
ever been previously implicated in any ocular disorders. FGD6
encodes for FYVE, RhoGEF and PH domain-containing
protein 6, with its functions yet to be characterized. The Q257R
mutation is less than half as common in Europeans (MAF¼ 0.10)
compared with East Asians (MAF¼ 0.20–0.30), again possibly
explaining the ability of our study to pick up this genetic effect.
The identiﬁed genes were expressed in human retinal pigment
epithelium (Supplementary Table 11). Of the three non-
synonymous substitutions, the CETP D442G variant was
predicted by both PolyPhen36 and SIFT37 to likely be causing
damage to the protein structure/function, the FGD6 Q257R
variant was predicted only by PolyPhen to be probably damaging
but by SIFT to be tolerated and the SLC44A4 D47V variant was
predicted by both tools to be benign or tolerated. Although the
use of both prediction algorithms has been reported to be
moderately sensitive, they suffer from lack of speciﬁcity38, and
thus more evidence should be sought with regards to the FDG6
and SLC44A4 non-synonymous variants.
Using HaploReg39, RegulomeDB40 and Encyclopaedia of DNA
Elements (ENCODE)41 data, we identiﬁed variants within each of
the four LD blocks in the 1000 Genomes Project (r240.8 and
o250 kb from the top SNP) to apply functional annotations
relevant to the regulation of transcription (Supplementary
Table 12). In addition to their functions on amino-acid
substitutions, all of the four identiﬁed variants lie within a
DNase I hypersensitivity site or in a region where modiﬁcation of
histones is suggestive of promoter, enhancer and other regulatory
activity, and/or have an inﬂuence on binding of transcription
factors or effects on a speciﬁc regulatory motif. C6orf223 A231A
(rs2295334) and FGD6 Q257R could tag genetic variants that lie
in potential transcription-factor binding sites (Supplementary
Table 13). Examination of a recently available large-scale eQTL
mapping database42 indicates that out of the four novel genome-
wide signiﬁcant SNPs, markers SLC44A4 D47V and FDG6 Q257R
could serve as cis-eQTLs. The minor allele at SLC44A4 D47V
(rs12661281) is associated with signiﬁcantly altered expression of
HSPA1B and CSKN2B, which are located within a 210,000 bp
region ﬂanking SLC44A4 D47V. The minor allele at FDG6 Q257R
(rs10507047) is associated with signiﬁcantly increased expression
of the neighbouring VEZT gene (Supplementary Table 14). Given
that these ﬁndings are based on expression in whole blood in
European samples, further work will be needed to elucidate their
role in retinal tissue and in Asian samples. Nonetheless, these
could suggest possible alternate mechanisms whereby both non-
synonymous substitutions potentially affect AMD risk apart from
directly affecting the protein structure of their parent genes.
Our study examined mainly the exudative subtype of AMD,
and therefore cannot be completely compared with other studies
looking at advanced AMD including the choroidal neovascular-
ization and geographic atrophy subtypes. We also note substantial
differences in inter-ethnic MAF for most of the previously
reported loci associated with AMD in European-ancestry
populations (Supplementary Table 1). This could represent
genuine differences in genetic architecture in AMD between
Asians and Europeans, or that the low allele frequency in either
ethnicity could result in insufﬁcient power to replicate genome-
wide signiﬁcant hits initially observed in either Asians or
Europeans. Overall, out of 21 previously reported SNPs showing
strong evidence of association in Europeans, we were able to
replicate 9 of them in our study of East Asians at Po0.05. Taken
together with the three novel loci and one novel variant in CETP
in East Asians discovered in this study, we postulate that the
genetic mechanisms of AMD in Asians could, in part, be
somewhat distinct from that in Europeans.
In summary, our genome-wide and exome-wide study of AMD
provides new insights into the genetic mechanisms of AMD in
East Asians. Our study highlights the value of searching for low-
frequency, ethnic-speciﬁc genetic variants on the coding frame of
AMD that may inform pathogenesis. Although some of the
genetic loci conferring disease susceptibility in East Asians are
shared with Europeans (for example, common variation mapping
to CFH, HTRA1 and CETP), we identiﬁed signiﬁcant important
differences in the ﬁne-scale genetic architecture of AMD, which
appear speciﬁc to East Asians. Such differences could underpin at
least some of the inter-ethnic differences in clinical presentation
and response to speciﬁc therapies, including the poorer response
to anti-VEGF therapy in Asians.
Methods
Study design and phenotyping. We performed a GWAS and EWAS on neo-
vascular AMD in East Asians. In the discovery stage, we included and genotyped
2,119 cases and 5,691 controls from three case–control studies from Singapore,
Hong Kong and Japan. For replication, ﬁve independent case–control studies were
conducted in Korea, Japan, and Guangdong, Sichuan and Beijing in China, total-
ling 4,226 cases and 10,289 controls. All the studies were performed with the
approval of their local Medical Ethics Committee, and written informed consent
was obtained from all the participants in accordance with the Declaration of
Helsinki.
A detailed description of subject recruitment and phenotyping in each sample
collection is provided in Supplementary Methods, and summarized in Table 1.
In brief, the diagnosis of exudative AMD was made at each site by retinal
specialists, according to standard clinical deﬁnitions on the basis of detailed
ophthalmic examinations, including dilated fundus photography, ﬂuorescein
angiography, indocyanine green angiography and optical coherence tomography
(Table 1). Grading of ﬂuorescein angiograms for the presence of choroidal
neovascularization were performed using a modiﬁcation from the Macular
Photocoagulation Study43. Indocyanine green angiography was performed to
diagnose deﬁnitive polypoidal choroidal vasculopathy, a variant of AMD, using the
Japanese Study Group guidelines44. Cases with other macular diseases such as
central serous chorioretinopathy, high myopia and angioid streaks were excluded.
Of the 2,119 exudative AMD cases included in the discovery phase, 1,083 (51%)
were classiﬁed as ‘typical neovascular AMD’, 1,015 (48%) were polypoidal
choroidal vasculopathy and 21 (1%) had one eye with typical neovascular AMD
and the other eye with polypoidal choroidal vasculopathy. At each site, controls
subjects without any clinical signs of AMD were either recruited from eye clinics or
enrolled from population-based studies (Supplementary Methods).
Genotyping and imputation. For the discovery stage, GWAS genotyping was
performed using the Illumina Human OmniExpress or Human Hap610-Quad
beadchips, and EWAS was done using HumanExome beadchips (Table 1). For
replication, genotyping was performed using the MassArray platform (Sequenom),
as well as using Taqman allelic discrimination probes (Applied Biosystems).
Stringent quality control ﬁlters were used to remove poorly performing samples
and SNP markers in both the discovery and replication (de-novo genotyping)
phases. For the GWAS, SNPs with a call rate ofo95%, MAF ofo1%, or showing
deviation from Hardy–Weinberg Equilibrium (Po10 6) were removed from
further statistical analysis. For the EWAS, SNPs with a call rate of o99%, MAF of
o0.1% or showing deviation from equilibrium (Po10 6) were removed. The 99%
threshold was used as many SNP markers on the exome array had MAFo5%, and
as such, differential genotyping success rates between cases and controls as low as
2% could result in false-positive ﬁndings. SNPs which were not monomorphic
(whereby at least one heterozygous carrier individual was present) were included
for downstream analysis.
Routine quality control criteria on a per-sample basis were carried out, and
poorly performing samples were removed from further analysis. The remaining
samples were then subjected to biological relationship veriﬁcation by using the
principle of variability in allele sharing according to the degree of relationship.
Identity-by-state information was derived using the PLINK software45. For those
pairs of ﬁrst-degree relatives so identiﬁed (for example, parent–offspring, full-
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siblings, as well as monozygous twins), we removed the sample with the lower call
rate before performing PC analysis.
The imputation was carried out using IMPUTE2 version 2.2.2 with ASN
population haplotypes from 1000 Genomes as reference, as described
elsewhere46–48. Imputed genotypes were called with an impute probability
threshold of 0.9 with all other genotypes classiﬁed as missing. Additional quality
control ﬁlters were applied to remove SNPs with41% missingness should the SNP
have a MAFo5% in either cases or controls. For common SNPS with MAF45%,
the ﬁltering criteria were set at 45% missingness.
Statistical analysis. For the discovery stage, all exudative AMD cases and controls
appear well matched when visualized spatially on PC analysis for each sample
collection on a per-country basis for Hong Kong, Japan and Singapore and
according to self-reported ethnicity (ethnic Chinese for Hong Kong and Singapore,
and ethnic Japanese for Japan; Supplementary Fig. 6), using previously reported
criteria49, indicating that population stratiﬁcation is unlikely to confound the
association results.
For both the discovery and replication stages, analysis of association with
exudative AMD was carried out using 1-degree of freedom score-based tests using
logistic regression. The tests model for a trend-per-copy effect of the minor allele
on disease risk. For the discovery stage, we incorporated the top ﬁve PCs of genetic
stratiﬁcation into the logistic regression model to minimize the effect of residual
population stratiﬁcation50. We could not adjust for population stratiﬁcation for the
replication stage due to limited number of SNPs tested. Meta-analysis was
conducted using inverse variance weights for each sample collection, which
calculates an overall Z-statistic, corresponding P value and accompanying per-allele
OR for each SNP analysed. Gene-based tests on mutational load was performed
using the SKAT-O test16. The association between CETP D442G and serum HDL-c
level was assessed using linear regression assuming an additive model of
inheritance as previously described23 (due to serum HDL-c being distributed
normally), with adjustment for age, gender and body mass index.
Regional association and PC plots were analysed and plotted using the
R statistical software package.
Power calculations. For the discovery stage (2,119 AMD cases and 5,691 con-
trols), power calculations51 indicated that there is 80% power of detecting loci at
Po1 10 4 (the threshold of association for bringing forward SNPs to the
replication stage) at MAF as low as 10% with per-allele OR of 1.30. For rarer
variants of higher penetrance, the discovery stage has 80% power of detecting loci
at Po1 10 4 at MAF as low as 2% if the per-allele OR is at least 1.70. The entire
sample (6,345 AMD cases and 15,980 controls) has 80% power to detect loci at
Po5.0 10 8 at MAF as low as 2% if the per-allele OR is at least 1.55 or at MAF
as low as 9% with per-allele OR of 1.25, in line with the effect sizes being reported
in this study. Supplementary Table 15A shows the power calculations to detect
SNPs at the threshold of Po1 10 4 in the discovery stage for bringing forward
to the replication stage. Supplementary Table 15B shows the formal power
calculations in the context of the combined discovery and replication stages.
References
1. Lim, L. S., Mitchell, P., Seddon, J. M., Holz, F. G. & Wong, T. Y. Age-related
macular degeneration. Lancet 379, 1728–1738 (2012).
2. Wong, W. L. et al. Global prevalence and burden of age-related macular
degeneration: a meta-analysis and disease burden projection for 2020 and 2040.
Lancet Glob. Health 2, e106–e116 (2014).
3. Spencer, K. L. et al. Protective effect of complement factor B and complement
component 2 variants in age-related macular degeneration. Hum. Mol. Genet.
16, 1986–1992 (2007).
4. Chen, W. et al. Genetic variants near TIMP3 and high-density lipoprotein-
associated loci inﬂuence susceptibility to age-related macular degeneration.
Proc. Natl Acad. Sci. USA 107, 7401–7406 (2010).
5. Yu, Y. et al. Common variants near FRK/COL10A1 and VEGFA are associated
with advanced age-related macular degeneration. Hum. Mol. Genet. 20,
3699–3709 (2011).
6. Fritsche, L. G. et al. Seven new loci associated with age-related macular
degeneration. Nat. Genet. 45, 433–439 439e431–432 (2013).
7. Raychaudhuri, S. et al. A rare penetrant mutation in CFH confers high risk of
age-related macular degeneration. Nat. Genet. 43, 1232–1236 (2011).
8. Seddon, J. M. et al. Rare variants in CFI, C3 and C9 are associated with high
risk of advanced age-related macular degeneration. Nat. Genet. 45, 1366–1370
(2013).
9. Helgason, H. et al. A rare nonsynonymous sequence variant in C3 is associated
with high risk of age-related macular degeneration. Nat. Genet. 45, 1371–1374
(2013).
10. Zhan, X. et al. Identiﬁcation of a rare coding variant in complement 3
associated with age-related macular degeneration. Nat. Genet. 45, 1375–1379
(2013).
11. Arakawa, S. et al. Genome-wide association study identiﬁes two susceptibility
loci for exudative age-related macular degeneration in the Japanese population.
Nat. Genet. 43, 1001–1004 (2011).
12. Laude, A. et al. Polypoidal choroidal vasculopathy and neovascular age-related
macular degeneration: same or different disease? Prog. Retin. Eye Res. 29, 19–29
(2010).
13. Cheung, C. M. & Wong, T. Y. Ranibizumab and bevacizumab for AMD
New Engl. J. Med. 365, 2237 author reply 2237 (2011).
14. van de Ven, J. P. et al. A functional variant in the CFI gene confers a high risk
of age-related macular degeneration. Nat. Genet. 45, 813–817 (2013).
15. Huyghe, J. R. et al. Exome array analysis identiﬁes new loci and low-frequency
variants inﬂuencing insulin processing and secretion. Nat. Genet. 45, 197–201
(2013).
16. Lee, S., Wu, M. C. & Lin, X. Optimal tests for rare variant effects in sequencing
association studies. Biostatistics 13, 762–775 (2012).
17. Inazu, A. et al. Genetic cholesteryl ester transfer protein deﬁciency caused by
two prevalent mutations as a major determinant of increased levels of high
density lipoprotein cholesterol. J Clin. Invest. 94, 1872–1882 (1994).
18. Barter, P. J. et al. Cholesteryl ester transfer protein: a novel target for
raising HDL and inhibiting atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 23,
160–167 (2003).
19. Lavanya, R. et al. Methodology of the Singapore Indian Chinese Cohort (SICC)
eye study: quantifying ethnic variations in the epidemiology of eye diseases in
Asians. Ophthalmic Epidemiol. 16, 325–336 (2009).
20. Sabanayagam, C. et al. Retinal arteriolar narrowing increases the likelihood of
chronic kidney disease in hypertension. J. Hypertens. 27, 2209–2217 (2009).
21. Cheung, C. M. et al. Prevalence of and risk factors for age-related macular
degeneration in a multiethnic Asian cohort. Arch. Ophthalmol. 130, 480–486
(2012).
22. Nakata, I. et al. Prevalence and characteristics of age-related macular
degeneration in the Japanese population: the nagahama study. Am. J.
Ophthalmol. 156, 1002–1009 e1002 (2013).
23. Kathiresan, S. et al. Six new loci associated with blood low-density lipoprotein
cholesterol, high-density lipoprotein cholesterol or triglycerides in humans.
Nat. Genet. 40, 189–197 (2008).
24. Kathiresan, S. et al. Common variants at 30 loci contribute to polygenic
dyslipidemia. Nat. Genet. 41, 56–65 (2009).
25. Hankin, J. H. et al. Singapore Chinese Health Study: development, validation,
and calibration of the quantitative food frequency questionnaire. Nutr. Cancer
39, 187–195 (2001).
26. Takeuchi, F. et al. Association of genetic variants inﬂuencing lipid levels with
coronary artery disease in Japanese individuals. PLoS ONE 7, e46385 (2012).
27. Takahashi, K. et al. A missense mutation in the cholesteryl ester transfer
protein gene with possible dominant effects on plasma high density
lipoproteins. J. Clin. Invest. 92, 2060–2064 (1993).
28. Freeman, D. J. et al. A polymorphism of the cholesteryl ester transfer protein
gene predicts cardiovascular events in non-smokers in the West of Scotland
Coronary Prevention Study. Eur. Heart J. 24, 1833–1842 (2003).
29. Howard, B. V. et al. LDL cholesterol as a strong predictor of coronary heart
disease in diabetic individuals with insulin resistance and low LDL: The Strong
Heart Study. Arterioscler. Thromb. Vasc. Biol. 20, 830–835 (2000).
30. Grundy, S. M. Low-density lipoprotein, non-high-density lipoprotein, and
apolipoprotein B as targets of lipid-lowering therapy. Circulation 106,
2526–2529 (2002).
31. Hara, R. et al. Photodynamic therapy alone versus combined with intravitreal
bevacizumab for neovascular age-related macular degeneration without
polypoidal choroidal vasculopathy in Japanese patients. Graefes Arch. Clin. Exp.
Ophthalmol. 248, 931–936 (2010).
32. Kumar, V. et al. Genome-wide association study identiﬁes a susceptibility
locus for HCV-induced hepatocellular carcinoma. Nat. Genet. 43, 455–458
(2011).
33. Su, Z. et al. Common variants at the MHC locus and at chromosome 16q24.1
predispose to Barrett’s esophagus. Nat. Genet. 44, 1131–1136 (2012).
34. O’Regan, S. et al. An electric lobe suppressor for a yeast choline transport
mutation belongs to a new family of transporter-like proteins. Proc. Natl Acad.
Sci. USA 97, 1835–1840 (2000).
35. Uhl, J. et al. Identiﬁcation of a CTL4/Neu1 fusion transcript in a sialidosis
patient. FEBS Lett. 521, 19–23 (2002).
36. Adzhubei, I. A. et al. A method and server for predicting damaging missense
mutations. Nat. Methods 7, 248–249 (2010).
37. Ng, P. C. & Henikoff, S. SIFT: predicting amino acid changes that affect protein
function. Nucleic Acids Res. 31, 3812–3814 (2003).
38. Flanagan, S. E., Patch, A. M. & Ellard, S. Using SIFT and PolyPhen to predict
loss-of-function and gain-of-function mutations. Genet. Test. Mol. Biomarkers
14, 533–537 (2010).
39. Ward, L. D. & Kellis, M. HaploReg: a resource for exploring chromatin states,
conservation, and regulatory motif alterations within sets of genetically linked
variants. Nucleic Acids Res. 40, D930–D934 (2012).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7063
8 NATURE COMMUNICATIONS | 6:6063 | DOI: 10.1038/ncomms7063 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
40. Boyle, A. P. et al. Annotation of functional variation in personal genomes using
RegulomeDB. Genome Res. 22, 1790–1797 (2012).
41. Consortium, E. P. et al. An integrated encyclopedia of DNA elements in the
human genome. Nature 489, 57–74 (2012).
42. Westra, H. J. et al. Systematic identiﬁcation of trans eQTLs as putative drivers
of known disease associations. Nat. Genet. 45, 1238–1243 (2013).
43. Laser photocoagulation of subfoveal neovascular lesions in age-related macular
degeneration. Results of a randomized clinical trial. Macular Photocoagulation
Study Group. Arch. Ophthalmol. 109, 1220–1231 (1991).
44. Japanese Study Group of Polypoidal Choroidal, V. [Criteria for diagnosis of
polypoidal choroidal vasculopathy]. Nihon Ganka Gakkai Zasshi 109, 417–427
(2005).
45. Purcell, S. et al. PLINK: a tool set for whole-genome association
and population-based linkage analyses. Am. J. Hum. Genet. 81, 559–575
(2007).
46. Marchini, J., Howie, B., Myers, S., McVean, G. & Donnelly, P. A new multipoint
method for genome-wide association studies by imputation of genotypes.
Nat. Genet. 39, 906–913 (2007).
47. Howie, B. N., Donnelly, P. & Marchini, J. A ﬂexible and accurate genotype
imputation method for the next generation of genome-wide association studies.
PLoS Genet. 5, e1000529 (2009).
48. Howie, B., Fuchsberger, C., Stephens, M., Marchini, J. & Abecasis, G. R.
Fast and accurate genotype imputation in genome-wide association studies
through pre-phasing. Nat. Genet. 44, 955–959 (2012).
49. Vithana, E. N. et al. Genome-wide association analyses identify three
new susceptibility loci for primary angle closure glaucoma. Nat. Genet.
44, 1142–1146 (2012).
50. Khor, C. C. et al. Genome-wide association study identiﬁes FCGR2A as a
susceptibility locus for Kawasaki disease. Nat. Genet. 43, 1241–1246 (2011).
51. Purcell, S., Cherny, S. S. & Sham, P. C. Genetic Power Calculator: design of
linkage and association genetic mapping studies of complex traits.
Bioinformatics 19, 149–150 (2003).
Acknowledgements
We thank the staff and participants of all studies for their important contributions. This
research was supported by the National Medical Research Council (NMRC grants 0796/
2003, IRG07nov013, IRG09nov014, NMRC 1176/2008, NIG/1003/2009, STaR/0003/
2008, CG/SERI/2010 and CSA/033/2012), and Biomedical Research Council (BMRC 08/
1/35/19/550, 09/1/35/19/616 and 10/1/35/19/671) in Singapore; BrightFocus Foundation
(M2011068), USA; the Seoul National University Bundang Hospital Research Grant
Fund (grant no. 03-2009-008), and National Research Foundation of Korea (NRF-2009-
0072603, NRF-2012R1A1A2008943, NRF-2014R1A2A1A09005824) grants funded by
the Ministry of Education, Science and Technology, Korea; and grants-in-aid for sci-
entiﬁc research (No. 24249082) from the Japan Society for the Promotion of Science,
Tokyo, Japan; the National Natural Science Foundation of China (81025006 (Z.Y.),
81170883 (Z.Y.) and the Department of Science and Technology of Sichuan Province,
China (2014SZ0169 (Z.Y.) and 2012SZ0219 (Z.Y.)). The Singapore Chinese Health Study
was founded by NUS-HUJ CREATE Programme of the National Research Foundation,
Singapore (Project No. 370062002), the National Medical Research Council (NMRC/
1270/2010), Singapore, and the National Institutes of Health, USA (NCI RO1 CA55069,
R35 CA53890, R01 CA80205 and R01 CA144034). C.-Y.C. is supported by an award
from NMRC (CSA/033/2012), Singapore. The Singapore Tissue Network and the Tissue
Repository of National University Health System provided services for DNA sample
storage in Singapore. The Genome Institute of Singapore, Agency for Science,
Technology and Research, Singapore provided services for genotyping.
Author contributions
C.-Y.C., K.Y., L.J.C., J.A., K.-H.P., C.P.P., N.Y., T.Y.W. and C.C.K. designed the study.
C.-Y.C., C.M.G.C., M.M., P.D.C., I.Y.Y., A.L., R.M., A.H.K., S.Y.L., D.W., C.M.G.C.,
B.K.L., Y.S., H.N., Y.A.-K., N.G., A.T., K.M., S.Y., Y.S., H.I., T.I., S.H., T.Y.Y.L., H.C., S.T.,
X.D., F.W., P.Z., B.Z., J.S., J.-M.Y., W.P.K., R.M.v.D., Y.F., N.W., G.S.W.T., S.J.P., M.B.,
L.G., T.N., P.M., P.Z., S.-M.S., M.O., T.M., Y.K., S.J.W., H.C., H.-G.Y., J.Y.S., D.H.P.,
I.T.K., W.C., M.S., S.-J.L., H.W.K., J.E.L., C.K.H., T.H.L., S.-K.Y., T.A. and W.T.Y.
gathered clinical data. J.P., S.D., I.N., Y.A.-K., F.M., P.O.S.T., F.L., X.Z., Y.S., B.G., R.D.,
Y.L., M.L.H., J.N.F., C.H.W., X.X., Jinlong Liang, J.M., X.J., Y.L., Jianjun Liu, K.S., E.N.V.,
J.X.B., Y.X.Z. and C.C.K. generated genetic data. C.-Y.C., K.Y., L.J.C., J.A., Lulin Huang,
Lvzhen Huang, K.S.S., P.C., Jiemin Liao, P.G.O., Y.Y.T. and C.C.K. analysed the data.
C.-Y.C., K.Y., L.J.C., J.A., Lulin Huang, Lvzhen Huang, E.S.T., X.X.L., Z.Y., K.H.P., C.P.P,
N.Y., T.Y.W. and C.C.K. interpreted the data. C.-Y.C., K.Y., L.J.C., J.A., E.S.T., T.Y.W.
and C.C.K. drafted the paper. All the authors contributed to revision of the paper.
Additional information
Supplementary Information accompanies this paper at http://www.nature.com/
naturecommunications
Competing ﬁnancial interests: The authors declare no competing ﬁnancial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
How to cite this article: Cheng, C.-Y. et al. New loci and coding variants confer risk for
age-related macular degeneration in East Asians. Nat. Commun. 6:6063 doi: 10.1038/
ncomms7063 (2015).
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated otherwise
in the credit line; if the material is not included under the Creative Commons license,
users will need to obtain permission from the license holder to reproduce the material.
To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7063 ARTICLE
NATURE COMMUNICATIONS | 6:6063 | DOI: 10.1038/ncomms7063 | www.nature.com/naturecommunications 9
& 2015 Macmillan Publishers Limited. All rights reserved.
Corrigendum: New loci and coding variants
confer risk for age-related macular degeneration
in East Asians
Ching-Yu Cheng, Kenji Yamashiro, Li Jia Chen, Jeeyun Ahn, Lulin Huang, Lvzhen Huang, Chui Ming G. Cheung,
Masahiro Miyake, Peter D. Cackett, Ian Y. Yeo, Augustinus Laude, Ranjana Mathur, Junxiong Pang, Kar Seng Sim,
Adrian H. Koh, Peng Chen, Shu Yen Lee, Doric Wong, Choi Mun Chan, Boon Kwang Loh, Yaoyao Sun,
Sonia Davila, Isao Nakata, Hideo Nakanishi, Yumiko Akagi-Kurashige, Norimoto Gotoh, Akitaka Tsujikawa,
Fumihiko Matsuda, Keisuke Mori, Shin Yoneya, Yoichi Sakurada, Hiroyuki Iijima, Tomohiro Iida, Shigeru Honda,
Timothy Yuk Yau Lai, Pancy Oi Sin Tam, Haoyu Chen, Shibo Tang, Xiaoyan Ding, Feng Wen, Fang Lu,
Xiongze Zhang, Yi Shi, Peiquan Zhao, Bowen Zhao, Jinghong Sang, Bo Gong, Rajkumar Dorajoo, Jian-Min Yuan,
Woon-Puay Koh, Rob M. van Dam, Yechiel Friedlander, Yin Lin, Martin L. Hibberd, Jia Nee Foo, Ningli Wang,
Chang Hua Wong, Gavin S. Tan, Sang Jun Park, Mayuri Bhargava, Lingam Gopal, Thet Naing, Jiemin Liao,
Peng Guan Ong, Paul Mitchell, Peng Zhou, Xuefeng Xie, Jinlong Liang, Junpu Mei, Xin Jin, Seang-Mei Saw,
Mineo Ozaki, Takinori Mizoguchi, Yasuo Kurimoto, Se Joon Woo, Hum Chung, Hyeong-Gon Yu, Joo Young Shin,
Dong Ho Park, In Taek Kim, Woohyok Chang, Min Sagong, Sang-Joon Lee, Hyun Woong Kim, Ji Eun Lee, Yi Li,
Jianjun Liu, Yik Ying Teo, Chew Kiat Heng, Tock Han Lim, Suk-Kyun Yang, Kyuyoung Song, Eranga N. Vithana,
Tin Aung, Jin Xin Bei, Yi Xin Zeng, E. Shyong Tai, Xiao Xin Li, Zhenglin Yang, Kyu-Hyung Park, Chi Pui Pang,
Nagahisa Yoshimura, Tien Yin Wong & Chiea Chuen Khor
Nature Communications 6:6063 doi: 10.1038/ncomms7063 (2015); Published 28 Jan 2015; Updated 30 Mar 2015
The ﬁnancial support for this Article was not fully acknowledged. The Acknowledgements should have included the following:
This study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded
by the Ministry of Education (2014055007), Ministry of Education, Science and Technology (2012004585), and by the Korea Health
Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A111345).
DOI: 10.1038/ncomms7817
NATURE COMMUNICATIONS | 6:6817 | DOI: 10.1038/ncomms7817 |www.nature.com/naturecommunications 1
& 2015 Macmillan Publishers Limited. All rights reserved.
